Target intelligence / Profile preview

Group B Streptococcus alpha-like protein (Alp)

Target
Alp
Molecular classification
Bacterial surface protein, Adhesin, Antigen
01

Overview

The Group B Streptococcus (GBS) alpha-like protein (Alp) family consists of several large surface-anchored proteins, including Alpha C, Rib, Alp1, Alp2, Alp3, Alp4, and R28, which are key virulence factors in Streptococcus agalactiae (UniProt P13515, P26753). These proteins are characterized by a conserved N-terminal domain and a variable number of identical tandem repeats that facilitate bacterial interaction with host tissues (PMID: 26055475). Biologically, Alp family members function as adhesins, enabling the bacteria to attach to and invade human epithelial cells in the vaginal and respiratory tracts (PMID: 15342475). They also play a critical role in immune evasion by interfering with opsonophagocytosis and protecting the pathogen from host clearance. Clinically, GBS is a leading cause of neonatal sepsis, meningitis, and pneumonia, making these proteins high-priority targets for vaccine development (PMID: 30452636). Current therapeutic strategies focus on using recombinant N-terminal domains or fusion proteins to induce broad-spectrum immunity across multiple GBS serotypes. Ongoing clinical trials, such as those for the GBS6 and Minervax vaccines, aim to prevent maternal colonization and vertical transmission to infants by targeting these conserved antigens.

Other names
Alpha-like protein familyAlpha C proteinRib proteinAlp1Epsilon proteinAlp2Alp3Alp4R28 proteinSurface protein AlpStreptococcus agalactiae alpha-like protein
02

Mechanism of action

Induction of protective IgG antibodies that neutralize bacterial adherence and promote opsonophagocytic killing by host immune cells.

03

Biological functions

Cell adhesionImmune evasionHost cell invasionProtection against opsonophagocytosis
04

Disease associations

InfectionNeonatal sepsisMeningitisPneumoniaMaternal infection
05

Safety considerations

Antigenic variation among different GBS strainsSerotype replacementPotential for immune interference in multi-antigen formulations
06

Interacting drugs

GBS6 (Hexavalent vaccine candidate)

4 more in the full profile.

07

Biomarkers

Anti-Alp IgG antibody titersGBS serotype-specific surface protein expression

Beyond the preview

Go deeper on Group B Streptococcus alpha-like protein (Alp).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Group B Streptococcus alpha-like protein (Alp).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call